GLMD Galmed Pharmaceuticals Ltd.

Price Chart

Executive Summary

Galmed Pharmaceuticals (GLMD) entered into a definitive agreement to acquire Colospan Ltd., a medical device company with a CE-marked intraluminal bypass device (CG-100) for colorectal anastomotic leak prevention. The total consideration is $4.5 million, comprising $2.5 million in cash and $2.0 million in GLMD ordinary shares. The acquisition positions Galmed as a GI-focused medtech and biopharma platform, with Colospan's CG-100 targeting a $6 billion market. The transaction is expected to close in Q2 2026.

Actionable Insight

Key Facts

• Galmed to acquire Colospan for $4.5M total consideration ($2.5M cash + $2.0M in GLMD shares).
• Colospan's CG-100 intraluminal bypass device is CE marked under MDR, has FDA Breakthrough Device Designation, and is in an active U.S. pivotal IDE trial.
• Galmed plans to invest at least $6M over 24 months post-closing to launch CG-100 in Europe (DACH countries) in H2 2026.
• Colospan's CG-100 targets a $6 billion total addressable market for colorectal anastomotic leak prevention.
• 7.5% of cash and shares placed in escrow for 12 months; Colospan options and warrants cancelled at closing.
• Colospan shareholders receiving shares are subject to a 24-month lock-up and must grant an irrevocable proxy to Galmed's board.
• Colospan had $910K cash, $3.727M in convertible SAFE notes, and an accumulated deficit of $16.52M as of Dec 31, 2025.
• Colospan has not generated any revenue; its auditor's report includes a going concern qualification.

Financial Impact

Total consideration of $4.5 million ($2.5M cash + $2.0M in shares). Galmed had $18.6M in total assets and $15.8M in stockholders' equity as of Dec 31, 2025. Pro forma combined cash is $2.1M. Goodwill and intangible assets of $4.2M recorded.

Risk Factors

• Transaction may not close if conditions (including Section 341 shareholder approval) are not met.
• Colospan's pivotal trial has enrolled only 57 of 228 target patients (17%) and has experienced prior delays and a voluntary pause.
• CG-100 faces entrenched competition from the standard-of-care diverting stoma and emerging intraluminal bypass startups (Safeheal, Averto Medical, JSR Medical).
• Colospan has no revenue history and a going concern qualification; post-acquisition cash burn may require additional financing.
• Integration risk: Galmed has no medtech commercialization experience.

Market Snapshot

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

US Market Status